Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1992-09-21
1994-10-04
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
A61K 31045
Patent
active
053527089
ABSTRACT:
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, either or thioether groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
REFERENCES:
patent: 4055602 (1977-10-01), Nelson
patent: 4171331 (1979-10-01), Biddlecom et al.
patent: 4183870 (1980-01-01), Caton
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
Prostaglandins: vol. 13, No. 5, May 1977, Stoneham, Mass., pp. 837-843, H. C. Arndt, "The Synthesis and Biological Activity of Prostaglandins Analogs Containing Spiroocyclic Rings".
Tetrahedron: vol. 32, 1976, Oxford GB, pp. 2747-2752, P. DeClercq et al, "Cyclopentanones-XV1,. Prostaglandin Synthesis Involving Catalytic Hydrogenation of 2,3-Dialkyl-4-Hydroxy-2-Cyclopentenones".
Derwent Publications Ltd., London, GB; AN 71-57222S & JP,A,46 030 830 (Ono Pharmaceutical Co).
Bito, Laszlo Z., "Prostaglandins, Old Concepts and New Perspectives," Arch Ophth. vol. 105, Aug. 1987 pp. 1036-1039.
Siebold, et al., "Esterified prostaglandin shows `potent` promise", Prodrug 5,3, Feb. 1, 1989.
Starr, Michael S., "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit," Exp. Eye Res., (1971) 170-177.
Nilsson, Siv F. E., et al., "PGF2a Increases Uveoscleral Outflow," ARVO Abstracts, p. 284 Invest. Ophthalmol. Vis.Sci. 28 (suppl) (1987).
Bito, Laszlo Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents," Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S. M. and Neufeld, A. H. eds, New York, Grune & Stratton, 1984 pp. 477-505.
Bito, Laszlo Z., "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents," Biological Protection with Prosataglandins (Cohen, M. M., ed., Boca Raton, Fla., CRC Press Inc., 1985, pp. 231-252.
Andrews Steven W.
Burk Robert M.
Garst Michael E.
Woodward David F.
Allergan Inc.
Baran Robert J.
Gerstl Robert
Lambert Howard R.
Voet Martin A.
LandOfFree
Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalky does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalky, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalky will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-581614